Fay Lin
@faylinphd.bsky.social
📤 55
📥 31
📝 25
Senior Technology Editor @ GEN Writing about AI x Bio ✉️
[email protected]
Genome foundation models, Evo 1 and Evo 2, have now generated viable bacteriophage genomes, demonstrating experimental validation of whole genomes designed by AI!
@arcinstitute.org
@brianhie.bsky.social
@samuelhking.bsky.social
Read more at GEN:
www.genengnews.com/topics/artif...
loading . . .
AI Designs Viable Bacteriophage Genomes, Combats Antibiotic Resistance
AI-guided design of 16 functional bacteriophage genomes offers a path for phage-based therapies against antibiotic-resistant infections.
https://www.genengnews.com/topics/artificial-intelligence/ai-designs-viable-bacteriophage-genomes-combats-antibiotic-resistance/
6 days ago
0
8
5
BindCraft is now published in
@nature.com
! The open-source pipeline for de novo protein binder design achieves significantly improved success rates with nanomolar affinity and therapeutic potential from gene editing to allergens. Read more at GEN:
www.genengnews.com/topics/artif...
loading . . .
BindCraft AI Model Achieves One-Shot Functional Protein Design
The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.
https://www.genengnews.com/topics/artificial-intelligence/bindcraft-ai-model-achieves-one-shot-functional-protein-design/
27 days ago
1
19
3
OpenCRISPR-1, Profluent's AI-designed gene editor, is now published in Nature!
@thisismadani.bsky.social
emphasizes the need to move away from random discovery and into bespoke design using AI. 1/ Read more at GEN:
www.genengnews.com/topics/artif...
loading . . .
Profluent’s AI-Designed Gene Editor Provides Glimpse Into Generalizable Platform
OpenCRISPR-1, an AI-generated custom gene editor capable of precision editing of the human genome. is just the beginning of Profluent’s AI applications.
https://www.genengnews.com/topics/artificial-intelligence/profluents-ai-designed-gene-editor-glimpses-into-generalizable-platform/
about 2 months ago
1
1
1
reposted by
Fay Lin
Elizabeth Wood, PhD
2 months ago
Great coverage of VISTA by the wonderful
@faylinphd.bsky.social
over at GEN:
www.genengnews.com/topics/artif...
Read about VISTA:
www.jurabio.com/blog/vista
loading . . .
Jura Bio’s AI Data Loop Enables Large-Scale De Novo Antibody Design
VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.
https://www.genengnews.com/topics/artificial-intelligence/jura-bios-ai-data-loop-enables-large-scale-de-novo-antibody-design/
0
8
3
David Baker's Nobel Prize-winning lab has now designed binders to "undruggable" disordered proteins, unlocking therapeutic access to over 50% of the human proteome! @uwproteindesign.bsky.social Read more at GEN:
tinyurl.com/4fw6wvkm
loading . . .
Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets
David Baker’s lab has successfully designed binders to disordered proteins, expanding therapeutic access to over 50% of the human proteome.
https://tinyurl.com/4fw6wvkm
2 months ago
0
3
1
reposted by
Fay Lin
Avner Schlessinger
3 months ago
Excited to see our new AI Small Molecule Drug Discovery Center
#MountSinai
featured in GEN! 🧬🧠 Read more:
genengnews.com/topics/artif...
Thank you
@faylinphd.bsky.social
#AI
#DrugDiscovery
#Genetics
loading . . .
Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery
While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.
https://genengnews.com/topics/artificial-intelligence/democratizing-artificial-intelligence-in-pre-clinical-drug-discovery/
0
4
1
@arcinstitute.org
has announced the inaugural “Virtual Cell Challenge,” sponsored by NVIDIA,
@10xgenomics.bsky.social
and Ultima Genomics, which will evaluate the ability of AI models to generalize to new cell contexts for therapeutic applications. 1/
www.genengnews.com/topics/artif...
loading . . .
Arc Institute Launches Virtual Cell Challenge to Accelerate AI Model Development
The open benchmark competition will evaluate the ability of AI-powered virtual cell models to generalize to new cell contexts for therapeutic applications.
https://www.genengnews.com/topics/artificial-intelligence/arc-institute-launches-virtual-cell-challenge-to-accelerate-ai-model-development/
3 months ago
1
1
2
Xaira Therapeutics has released the largest publicly available Perturb-seq dataset to train the AI-powered virtual cell for drug discovery! The work is described in Xaira's first preprint, capping a year after the company's $1 billion launch.
www.genengnews.com/topics/artif...
loading . . .
Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell
The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.
https://www.genengnews.com/topics/artificial-intelligence/xaira-therapeutics-releases-largest-perturb-seq-dataset-to-power-the-virtual-cell/
3 months ago
0
0
0
reposted by
Fay Lin
True Ventures
3 months ago
More in GEN from
@faylinphd.bsky.social
:
www.genengnews.com/topics/artif...
loading . . .
Million Species Listing: Basecamp Research Unearths Trove of Sequence Data From Novel Species
BaseData aims to improve AI models in biology by offering a 10-fold expansion of protein diversity compared to all public databases combined.
https://www.genengnews.com/topics/artificial-intelligence/million-species-listing-basecamp-research-unearths-trove-of-sequence-data-from-novel-species/
0
1
1
Boltz-2 now predicts molecular binding affinity at newfound speed and accuracy - and it's open source! The permissive MIT license allows commercial drug developers to apply proprietary data and offers an advance over the structure prediction capabilities of AlphaFold 3.
tinyurl.com/37c96c6y
loading . . .
Boltz-2 Released to Democratize AI Molecular Modeling for Drug Discovery
The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.
https://www.genengnews.com/topics/artificial-intelligence/boltz-2-released-to-democratize-ai-molecular-modeling-for-drug-discovery/
4 months ago
1
18
4
AI hype or reality - can we design antibodies from scratch (de novo)? In my latest for GEN, I unpack where de novo design is today and how arguments over terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.
tinyurl.com/4uamc8c5
loading . . .
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox
Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster.
https://tinyurl.com/4uamc8c5
4 months ago
0
0
0
reposted by
Fay Lin
Kevin Davies
4 months ago
Excellent story from
@faylinphd.bsky.social
on the hot news from
#ASGCT2025
—
@kiranmusunuru.bsky.social
and colleagues tailor the world’s first bespoke gene editor to treat KJ, an infant with an ultra-rare genetic disease, heralding a new era in precision med.
www.genengnews.com/topics/genom...
0
6
2
reposted by
Fay Lin
IMPRINT
4 months ago
📣Major thanks to
@faylinphd.bsky.social
at GEN News for this lovely piece on IMPRINT! It was a pleasure for our founders —
@beckbrachman.bsky.social
,
@victorgreiff.bsky.social
, and Raymond Alvarez — to speak about our mission and research, and being NYC's first FRO.
@convergentresearch.bsky.social
loading . . .
Imprint Labs Launches to Pioneer "Forensic Immunology" For Chronic Disease
Imprint has raised $15 million to decode the body's immune memory for understanding chronic diseases, such as long-COVID and psychiatric disorders.
https://www.genengnews.com/gen-edge/imprint-labs-launches-to-pioneer-forensic-immunology-for-chronic-disease/
0
3
4
BREAKING NEWS: World’s first patient treated with personalized CRISPR therapy! Born with a severe metabolic disease with a 50% mortality rate, an infant has improved after receiving an individualized gene editing therapy, a glimpse of a new era in genomic precision medicine.
tinyurl.com/m52udxht
loading . . .
ASGCT 2025: World’s First Patient Treated with Personalized CRISPR Therapy
Treated with an individualized gene-editing therapy that corrects mutations directly on the genome, a patient shows improvement from a rare metabolic disease.
https://www.genengnews.com/topics/genome-editing/asgct-2025-worlds-first-patient-treated-with-personalized-crispr-therapy/
4 months ago
0
0
0
Introducing TranscriptFormer, the cross-species cell atlas! This new generative
#AI
model from
@chanzuckerberg.bsky.social
is trained on data from over 110 million cells from 12 different species, covering 1.5 billion years of evolution.
tinyurl.com/2yet8k42
loading . . .
The Cross-Species Cell Atlas: Chan Zuckerberg Initiative Releases TranscriptFormer AI Model
Trained on data covering 1.5 billion years of evolution, CZI’s new generative AI model probes cellular biology across species for therapeutic applications.
https://www.genengnews.com/topics/artificial-intelligence/the-cross-species-cell-atlas-chan-zuckerberg-initiative-releases-transcriptformer-ai-model/
5 months ago
1
1
2
reposted by
Fay Lin
Ben Kleinstiver
5 months ago
Thanks to
@faylinphd.bsky.social
from @GEN for featuring our manuscript!
www.genengnews.com/topics/genom...
loading . . .
Machine Learning Engineers Bespoke Cas9 Enzymes for Gene Editing
Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.
https://www.genengnews.com/topics/genome-editing/machine-learning-engineers-bespoke-cas9-enzymes-for-gene-editing/
0
1
1
New from
@arcinstitute.org
is "the largest publicly available
#AI
model for biology to date"! Evo 2 now includes information from all domains in life to expand its capabilities in generative functional genomics.
@pdhsu.bsky.social
@brianhie.bsky.social
tinyurl.com/3t83vseh
loading . . .
Arc Institute’s AI Model Evo 2 Designs the Genetic Code Across All Domains of Life
Evo 2 now includes information from humans, plants, and other eukaryotic species to expand its capabilities in generative functional genomics.
https://tinyurl.com/3t83vseh
7 months ago
0
1
1
Leveraging protein structure prediction tools, researchers from Northwestern University present an
#AI
based framework to uncover potential structural design rules across receptor families for improved cell therapies. Read more at GEN:
www.genengnews.com/topics/artif...
loading . . .
AI-Guided Receptor Engineering to Improve Performance in Cell Therapies
Using protein structure prediction tools, researchers have uncovered receptor structure-function relationships to improve cell therapies.
https://www.genengnews.com/topics/artificial-intelligence/ai-guided-receptor-engineering-to-improve-performance-in-cell-therapies/
7 months ago
0
1
0
reposted by
Fay Lin
Kevin Davies
8 months ago
Congrats to
@faylinphd.bsky.social
on her first exclusive story for GEN - Recursion presents promising phase II data on its AI drug for CCM:
www.genengnews.com/topics/artif...
loading . . .
Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease
Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.
https://www.genengnews.com/topics/artificial-intelligence/recursion-announces-promising-clinical-data-on-lead-ai-based-drug-candidate-for-brain-disease/
0
1
1
EXCLUSIVE:
@recursionpharma.bsky.social
announced favorable efficacy data in the Phase 2 trial for REC-994, the company’s lead AI-derived candidate to treat the potentially fatal brain disease, cerebral cavernous malformation (CCM). My latest for GEN:
tinyurl.com/yc6wspz5
1/
loading . . .
Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease
Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.
https://tinyurl.com/yc6wspz5
8 months ago
1
1
0
you reached the end!!
feeds!
log in
